Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions

Background: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide–formoterol (DuoResp) Spiromax; flow rates through empty versions...

Descripción completa

Detalles Bibliográficos
Autores principales: Canonica, Giorgio Walter, Arp, Jan, Keegstra, Johan René, Chrystyn, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/
https://www.ncbi.nlm.nih.gov/pubmed/26352860
http://dx.doi.org/10.1089/jamp.2015.1216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601554/
https://www.ncbi.nlm.nih.gov/pubmed/26352860
http://dx.doi.org/10.1089/jamp.2015.1216

Ejemplares similares